ARTICLE | Company News
Vectura, Novartis sales and marketing update
January 27, 2014 8:00 AM UTC
Novartis' Sandoz generic pharmaceuticals division launched AirFluSal Forspiro salmeterol/fluticasone in Denmark to treat patients 12 years and older with asthma and chronic obstructive pulmonary disease (COPD). The product is approved in Denmark, Germany, Sweden and Hungary under the EU's decentralized procedure. The companies could not be reached for details on pricing (see BioCentury, Jan. 20). ...